cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma

Transl Lung Cancer Res. 2020 Jun;9(3):807-810. doi: 10.21037/tlcr-20-442.

Qiong He^{1

2

3}, Xian Zhu⁴, Xun Shi^{1

2

3}, Chen Lin^{1

2

3}, Yin Jin^{1

2

3}, Junrong Yan⁵, Jiachen He⁵, Xinmin Yu^{1

2

3}

¹ Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
² Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China.
³ Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
⁴ Department of Cardiovascular Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310022, China.
⁵ Nanjing Geneseeq Technology Inc., Nanjing 210032, China.

No abstract available